Earnings Feed
Start Free
Home/Filings/4/0001665124-26-000002
4//SEC Filing

Nagendran Sukumar 4

Accession 0001665124-26-000002

CIK 0001806310other
View on SEC.govCompany Profile

Filed

Jan 13, 7:00 PM ET

Accepted

Jan 14, 4:45 PM ET

Size

17.4 KB

Accession

0001665124-26-000002

Insider Transaction Report

Form 4
Period: 2026-01-12
Taysha Gene Therapies, Inc.TSHA
Nagendran Sukumar
DirectorPresident and Head of R&D
Transactions
  • Exercise/Conversion

    Common Stock

    2026-01-12$0.70/sh+111,324$77,804→ 1,117,763 total
  • Exercise/Conversion

    Common Stock

    2026-01-12$1.71/sh+88,676$151,636→ 1,206,439 total
  • Sale

    Common Stock

    [F1][F2]
    2026-01-12$4.71/sh−200,000$942,000→ 1,006,439 total
  • Award

    Common Stock

    [F3]
    2026-01-12+427,000→ 1,433,439 total
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    [F4]
    2026-01-12−111,324→ 111,359 total
    Exercise: $0.70Exp: 2033-12-14→ Common Stock (111,324 underlying)
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    [F5]
    2026-01-12−88,676→ 474,941 total
    Exercise: $1.71Exp: 2034-01-02→ Common Stock (88,676 underlying)
  • Award

    Employee Stock Option (right to buy)

    [F6]
    2026-01-12+274,000→ 274,000 total
    Exercise: $4.86Exp: 2036-01-12→ Common Stock (274,000 underlying)
Footnotes (6)
  • [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
  • [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.565 to $4.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.
  • [F4]The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.
  • [F5]25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
  • [F6]25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Signature
/s/ Kamran Alam, Attorney-in-Fact|2026-01-14

Documents

1 file

Issuer

Taysha Gene Therapies, Inc.

CIK 0001806310

→
Entity typeother

Related Parties

1
  • filerCIK 0001665124

Filing Metadata

Form type
4
Filed
Jan 13, 7:00 PM ET
Accepted
Jan 14, 4:45 PM ET
Size
17.4 KB
View on SEC.gov